U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778836) titled 'A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia' on Aug. 17.
Brief Summary: To evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia
Study Start Date: Aug. 05
Study Type: INTERVENTIONAL
Condition:
Friedreich Ataxia
Friedreich's Ataxia
Intervention:
DRUG: Nomlabofusp
Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
DRUG: Placebo
The placebo i...